Methods and compositions for reducing ocular discomfort
The invention relates to compositions and devices which include an osmolytic agent, in particular a betaine or carnitine compound, for reducing ocular discomfort associated with various diseases or conditions, in particular diseases or conditions associated with high tear film tonicity. The invention also relates to methods of treating or preventing various diseases or conditions using compositions and devices of the invention.
1. A method for inhibiting, reducing or ameliorating ocular discomfort associated with high tear film tonicity in a subject comprising:
applying an ophthalmic device comprising:
a mixture of osmolytic agents, comprising:
between 5 and 20 mM of one or more carnitine compounds and between 5 and 20 mM of one or more betaine compounds; and
a diffusion attenuator;
wherein the ophthalmic device permits the mixture of osmolytic agents to be desorbed from the ophthalmic device into the eye during wear.
2. A method according to claim 1 , wherein the method includes a step of determining whether a subject has or is at risk of developing tear film with high tonicity prior to applying the ophthalmic device.
3. A method according to claim 1 , wherein the subject has Dry Eye Syndrome.
4. A method according to claim 1 , wherein the betaine compound has a molecular weight of about 600 Da or less.
5. A method according to claim 1 , wherein the betaine compound has a molecular weight of about 250 Da less.
6. A method according to claim 1 , wherein the betaine compound is selected from the group consisting of trimethylglycine, proline betaine, betaine hydrochloride, beta-alanine betaine, hydroxyproline betaine, cocamidopropylbetaine, carbethoxymethyltrimethylammonium hydroxide and analogs thereof.
7. A method according to claim 1 , wherein the betaine compound is selected from the group consisting of trimethylglycine, praline betaine, betaine hydrochloride, beta-alanine betaine and hydroxyproline betaine.
8. A method according to claim 1 , wherein the carnitine compound is selected from the group consisting of L-carnitine, alkanoyl L-carnitines including those selected from the group consisting of acetyl, propionyl, isovaleryl, butyryl, and isobutyryl L-carnitine and their pharmaceutically acceptable salts.
9. A method according to claim 1 , wherein the carntine compound is L-carnitine.
10. A method according to claim 1 , wherein the ophthalmic device is a single use contact lens.
11. A method according to claim 1 , wherein the ophthalmic device permits a therapeutically effective amount of the osmolytic agent to be desorbed over about a 12 hour period.
12. A method according to claim 1 , wherein the diffusion attenuator is vitamin E.
13. A method according to claim 1 , wherein the concentration of the one or more betaine compounds present in the ophthalmic device is 20 mM.
14. A method according to claim 13 , wherein the betaine compound is selected from the group consisting of trimethylglycine, proline betaine, betaine hydrochloride, beta-alanine betaine, hydroxyproline betaine, cocamidopropylbetaine, carbethoxymethyltrimethylammonium hydroxide and analogs thereof.
15. A method according to claim 14 , wherein the betaine compound is selected from the group consisting of trimethylglycine, praline betaine, betaine hydrochloride, beta-alanine betaine and hydroxyproline betaine.
16. A method according to claim 15 , wherein the concentration of the one or more betaine compounds present in the contact lens is 10 mM.
17. A method according to claim 1 , wherein the concentration of the one or more carnitine compounds present in the ophthalmic device is 20 mM.
18. A method according to claim 17 , wherein the carnitine compound is selected from the group consisting of L-carnitine, alkanoyl L-carnitines including those selected from the group consisting of acetyl, propionyl, isovaleryl, butyryl, and isobutyryl L-carnitine and their pharmaceutically acceptable salts.
19. A method according to claim 18 , wherein the carntine compound is L-carnitine.
20. A method according to claim 19 , wherein the concentration of the one or more carnitine compounds present in the ophthalmic device is 10 mM.